MedPage Today -- HOUSTON, May 13 -- Older women with early-stage breast cancer fared better with conventional adjuvant chemotherapy than with the newer agent capecitabine (Xeloda) in a large multicenter clinical trial.
MedPage Today -- HOUSTON, May 13 -- Older women with early-stage breast cancer fared better with conventional adjuvant chemotherapy than with the newer agent capecitabine (Xeloda) in a large multicenter clinical trial.